Edwards Lifesciences Corp (EW)
Edwards Lifesciences Corp is a healthcare company focused on products and technologies for advanced cardiovascular disease. Its portfolio includes transcatheter heart valve replacement systems for minimally invasive aortic valve replacement, marketed under the Edwards SAPIEN family, as well as transcatheter repair and replacement solutions for mitral and tricuspid valve conditions, including PASCAL and EVOQUE. The company also develops surgical structural heart products such as the INSPIRIS aortic valve, INSPIRIS RESILIA aortic valve, KONECT RESILIA conduit, and MITRIS RESILIA valve. Edwards Lifesciences sells its products through a direct sales force and independent distributors. Founded in 1958, the company is headquartered in Irvine, California, and operates in the United States, Europe, Japan, and other international markets.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-EW
|
$90.24
|
2.2% Upside
|
Fair
|
$100.96
|
14.4% Upside
|
Fair
|
Great
|
0.0%
|
October 28, 2026
|
51.9x
|
4.8x
|
7.8x
|
50.873 B
|
47.397 B
|
1.4%
|
99.7%
|
13.5
|
146.3%
|
